Advertisement

Topics

China’s 3SBio enters North American market through $290m Therapure buy

07:44 EDT 5 Sep 2017 | BioPharma-Reporter

3SBio will leverage Therapure’s downstream purification expertise to bolster its own biologics portfolio while expanding its contract biomanufacturing business and global presence.

Original Article: China’s 3SBio enters North American market through $290m Therapure buy

NEXT ARTICLE

More From BioPortfolio on "China’s 3SBio enters North American market through $290m Therapure buy"

Quick Search
Advertisement
 

Relevant Topic

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...